CAMCEVI leuprolide mesylate

Drug Class

Gonadotropin-releasing hormone (GnRH) receptor agonist

Mechanism

Provides continuous stimulation of GnRH receptors in the pituitary gland, leading to receptor downregulation and suppression of luteinizing hormone (LH) and testosterone.

Approved Indication

Advanced prostate cancer, per its FDA approval.

What This Means For Patients

CAMCEVI is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2021) — Sources

Pivotal Clinical Evidence

• FP01C-13-001 — Shore et al., World J Urol 2020 (NCT02234037) — Sources

Sources

• https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-leuprolide-mesylate-advanced-prostate-cancer
• https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212166